4-(6-甲氧基-2-甲基吡啶-3-基)-3-甲基-1H-吡唑-5-胺 | 459856-15-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-(6-甲氧基-2-甲基吡啶-3-基)-3-甲基-1H-吡唑-5-胺
• 英文名称: 5-amino-4-(2-methyl-6-methoxypyrid-3-yl)-3-methylpyrazole
• 英文别名: 4-(6-Methoxy-2-methylpyridin-3-yl)-3-methyl-1H-pyrazol-5-amine；4-(6-methoxy-2-methylpyridin-3-yl)-5-methyl-1H-pyrazol-3-amine
• CAS: 459856-15-6；1266353-34-7
• 化学式: C₁₁H₁₄N₄O
• 分子量: 218.258
• InChiKey: DBYXJRKHSRAILN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  76.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(6-甲氧基-2-甲基吡啶-3-基)-3-甲基-1H-吡唑-5-胺 、 1-乙氧基乙基亚基氯化铵 在 1-乙氧基乙基亚基氯化铵 作用下， 生成 acetic acid;N'-[4-(6-methoxy-2-methylpyridin-3-yl)-5-methyl-1H-pyrazol-3-yl]ethanimidamide
  参考文献：
  名称：

  4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

  摘要：

  Corticotropin releasing factor (CRF)拮抗剂的化学式(I):1及其在治疗焦虑、抑郁和其他精神、神经系统疾病方面的应用，以及治疗与心理病理障碍和压力相关的免疫、心血管或心脏相关疾病和结肠过敏反应。

  公开号：

  US20030125330A1
• 作为产物：
  描述：

  2-methyl-3-(5-methylisoxazol-4-yl)-6-methoxypyridine 在 sodium methylate 、 一水合肼 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 反应 20.0h， 以5.8 g的产率得到4-(6-甲氧基-2-甲基吡啶-3-基)-3-甲基-1H-吡唑-5-胺
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of 8-(Pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: Potent, Orally Bioavailable Corticotropin Releasing Factor Receptor-1 (CRF₁) Antagonists

  摘要：

  This report describes the syntheses and structure-activity relationships of 8-(substituted pyridyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF1) receptor antagonists. These CRF1 receptor antagonists may be potential anxiolytic or antidepressant drugs. This research resulted in the discovery of compound 13-15, which is a potent, selective CRF1 antagonist (hCRF(1) IC50 = 6.1 +/- 0.6 nM) with weak affinity for the CRF-binding protein and biogenic amine receptors. This compound also has a good pharmacokinetic profile in dogs. Analogue 13-15 is orally effective in two rat models of anxiety: the defensive withdrawal (situational anxiety) model and the elevated plus maze test. Analogue 13-15 has been advanced to clinical trials.

  DOI：

  10.1021/jm900025h

文献信息

• 4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
  申请人：——

  公开号：US20030125330A1

  公开（公告）日：2003-07-03

  Corticotropin releasing factor (CRF) antagonists of Formula (I): 1 and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

  Corticotropin releasing factor (CRF)拮抗剂的化学式(I): 1及其用于治疗焦虑、抑郁和其他精神、神经系统疾病，以及治疗免疫、心血管或与心脏相关的疾病和与心理病理紊乱和压力相关的结肠过敏反应。
• [EN] 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO-[1,5-A]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS<br/>[FR] 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO-[1,5-A]-1,3,5-TRIAZINE, SES ENANTIOMERES ET SELS PHARMACEUTIQUEMENT ACCEPTABLES EN TANT QUE LIGANDS DU RECEPTEUR DE LA CORTICOLIBERINE
  申请人：BRISTOL MYERS SQUIBB PHARMA CO

  公开号：WO2002072202A1

  公开（公告）日：2002-09-19

  Corticotropin releasing factor (CRF) antagonists of Formula (I), and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

  Corticotropin releasing factor (CRF) Formula (I) 的拮抗剂，用于治疗焦虑、抑郁和其他精神、神经障碍，以及治疗免疫、心血管或与心脏相关的疾病和与心理病理扰乱和压力相关的结肠过敏性。
• 4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
  申请人：Gilligan J. Paul

  公开号：US20070054913A1

  公开（公告）日：2007-03-08

  Corticotropin releasing factor (CRF) antagonists of Formula (I): and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

  Corticotropin releasing factor (CRF)拮抗剂的化学式（I）及其在治疗焦虑、抑郁和其他精神、神经系统疾病方面的用途，以及治疗与心理病理障碍和压力相关的免疫、心血管或心脏疾病和结肠过敏反应。
• 4- (2-butylamino) -2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-YL) pyrazolo- [1,5-A] -1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
  申请人：——

  公开号：US20040014760A1

  公开（公告）日：2004-01-22

  Corticotropin releasing factor (CRF) antagonists of Formula (I): 1 and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

  式（I）的促皮质素释放因子（CRF）拮抗剂： 1 及其在治疗焦虑症、抑郁症和其他精神、神经疾病以及免疫、心血管或心脏相关疾病和与精神病理紊乱和压力相关的结肠超敏反应方面的用途。
• 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-A]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1368094A1

  公开（公告）日：2003-12-10